iBio Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio or view top-rated stocks.

Wall Street analysts have given iBio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

iBio is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for iBio.

iBio will be holding an earnings conference call on Monday, September 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biotechnology company had revenue of $0.77 million for the quarter. iBio had a negative net margin of 895.37% and a negative trailing twelve-month return on equity of 30.81%.
View iBio's earnings history.

Shares of iBio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

2 analysts have issued 12-month target prices for iBio's shares. Their forecasts range from $2.00 to $3.00. On average, they expect iBio's stock price to reach $2.50 in the next year. This suggests a possible upside of 115.5% from the stock's current price.
View analysts' price targets for iBio or view top-rated stocks among Wall Street analysts.

Some companies that are related to iBio include Phathom Pharmaceuticals (PHAT), Kinnate Biopharma (KNTE), RAPT Therapeutics (RAPT), Stoke Therapeutics (STOK), Omeros (OMER), Prometheus Biosciences (RXDX), Nkarta (NKTX), FibroGen (FGEN), ORIC Pharmaceuticals (ORIC), BELLUS Health (BLUSF), Vanda Pharmaceuticals (VNDA), IDEAYA Biosciences (IDYA), Celularity (CELU), Gossamer Bio (GOSS) and Edgewise Therapeutics (EWTX).
View all of IBIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.14%), Vanguard Group Inc. (4.80%), State Street Corp (1.77%), Geode Capital Management LLC (1.64%), Northern Trust Corp (0.92%) and Susquehanna International Group LLP (0.00%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio.

IBIO stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., JPMorgan Chase & Co., Bank of America Corp DE, Northern Trust Corp, Millennium Management LLC, Vanguard Group Inc., Price T Rowe Associates Inc. MD, and Invesco Ltd..
View insider buying and selling activity for iBio or view top insider-selling stocks.

IBIO stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Susquehanna International Group LLP, Squarepoint Ops LLC, Nuveen Asset Management LLC, Geode Capital Management LLC, Marshall Wace LLP, Marshall Wace LLP, and Man Group plc.
View insider buying and selling activity for iBio or or view top insider-buying stocks.

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $1.16.

iBio has a market capitalization of $252.71 million and generates $1.64 million in revenue each year. The biotechnology company earns $-16,440,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

iBio employs 47 workers across the globe.

The official website for iBio is www.ibioinc.com.

iBio is headquartered at 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at (302) 355-0650 or via email at [email protected].